Although multiple sclerosis (MS) treatments have improved, they often cause severe side effects and fail to halt disease progression in some patients. There is an urgent need for personalized therapies based on the individual's specific disease characteristics. Identifying predictive biomarkers for MS remains a challenge.
This project proposes a novel multiomic approach combining serum lipidomics, single-cell transcriptomics, and functional single-cell analysis to study dysregulated and autoreactive immune cells in MS patients. The aim is to analyze rare, activated immune cells to understand their heterogeneity and functionality, helping to stratify patients for tailored therapies.
This project will be primarily hosted in Aarhus with Klaus, and secondments are planned with Gijs Kooij in Amsterdam and Lara at the University of Bielefeld.
